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INTRODUCTION
Altered fatty acid (FA) metabolism is a hallmark of many chronic non-communicable diseases,
including atherosclerosis, cardiovascular disease (CVD), diabetes and inflammatory diseases
(Lecerf, 2009; Ristic-Medic et al., 2009; Ristić-Medić et al., 2013). Of particular importance is the
role of FAs in the formation of eicosanoids, which are a group of signaling molecules involved in
immune response (Vučić, 2013). In contrast to the negative effects of saturated (SFA) and trans fatty
acids, the intake of both monounsaturated (MUFAs) and ω-3 and ω-6 polyunsaturated fatty acids
(PUFAs) is associated with beneficial effects on atherosclerosis (Herold and Kinsella, 1986; Flachs
et al., 2009). Among other functions, these FAs increase the uptake of circulating LDL-cholesterol
by the liver and reduce leukocyte activation, platelet reactivity, lymphocyte proliferation, and blood
pressure (Houston, 2007).
Homocysteine (Hcy) is a sulfur amino acid involved in many biological processes (Kapoor and
Huang, 2006; Jacobson, 2007). It is firmed during demethylation process of methionine from diet
from animal proteins.We know that theHcy could be present in various forms: free as thiol, in form
of sulfide and in form of dimer with other thiols (Metcalf et al., 2003; Faeh et al., 2006). Hcy is a key
determinant of the methylation cycle, and hyperhomocysteinemia (Hhcy) is defined as a medical
disorder characterized by abnormally high levels (above 15 µmol/L) of circulated homocysteine
in the blood. Hhcy could be a marker of endothelial dysfunction and vascular disease as well as
disturbance of homeostasis (Hankey and Eikelboom, 1999).
Hcy has a role in atherosclerotic processes, and there are different therapeutic options indicating
the slowing progression of these processes in vessels (Loscalzo and Handy, 2014). The most
important therapeutic agents in dyslipidaemia are statins or hydroxy-methyglutaryl coenzyme
A (HMG-CoA) reductase inhibitors, which are widely used in lowering the cholesterol levels in
preventing and treatment of cardiovascular disorders (Harvey and Ferrier, 2011). Also, several
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dietary components, such as PUFAs, could decrease
cardiovascular risk in patients, but there is little data about the
relationship between fatty acid status and homocysteine levels.
Previous studies have found that dietary FAs interact
with methylenetetrahydrofolate reductase (MTHFR) and
enzyme such as methionine adenosyltransferase I, which are
alpha (MAT1A) genetic variants for determining plasma Hcy
concentrations (Maron et al., 2000; Palinski, 2001). In contrast,
acetyl coenzyme A carboxylase and fatty acid synthase, could be
involved in regulation of FA biosynthesis, as enzymes and can be
simultaneously controlled by HMG-CoA reductase enzyme at
the molecular level (Greenwood et al., 2006; Wang et al., 2008).
These mentioned mechanisms are associated with Hhcy and
statin treatment (Maron et al., 2000; Palinski, 2001; Greenwood
et al., 2006; Wang et al., 2008).
The present study examines the levels Hcy and FAs in
total plasma lipids from animals fed standard and methionine-
enriched diets, as well as the changes in FA profiles during
treatment with two different statins, atorvastatin or simvastatin,
at therapy-equivalent doses. Moreover, the present study also
examines the correlations between the FA profile and Hcy levels,
which are implicated in the pathology of cardiovascular diseases.
MATERIALS AND METHODS
Ethical Concerns
All experiment and procedures were performed in accordance
with valid European guidelines regarding the experiments with
animals (European Directive for welfare of laboratory animals
No: 2010/63/EU). Also, our protocol of study was evaluated,
checked and approved by an institutional committee (Faculty
of Medical Sciences, University of Kragujevac, Serbia Ethics
committee for well-being of experimental animals, Number of
approval: 01-11794).
Experimental Design
Before the experimental procedures, all rats (n = 72; 8 rats per
group;Wistar albino male rats) were in adaptation period for two
weeks in the animal house at the Faculty of Medical Sciences in
Kragujevac. After that started dietary manipulation with three
different diets separately. Animals have ad libitum water and
food in standard laboratory controlled conditions (22 ± 2◦C;
light/dark cycle 12:12 h; two rats per cage). All animals were
divided into the next groups:
1. Control group-Standard food for rodents (S);
2. Methionine group-Methionine-enriched food (M)
3. Methionine-enriched and folate-deficient group-Methionine
enriched and deficient in deficiency in B vitamins (folic acid,
B6 and B12) (MFD);
4. Atorvastatin group-Standard food for rodent plus 3
mg/kg/day i.p of atorvastatin (S+ATO);
5. Simvastatin group-Standard food for rodents plus 5
mg/kg/day i.p simvastatin (S+SIM);
6. Methionine plus atorvastatin group (M+ATO);
7. Methionine plus simvastatin group (M+SIM);
8. Methionine enriched and folate-deficient plus atorvastatin
group (MFD+ATO);
9. Methionine enriched and folate-deficient plus simvastatin
group (MFD+SIM);
The rats were weighed when they were assigned to treatment
groups and subsequently every day. The food intake was
measured daily, always at the same time during the 4-week
experimental period, prior to euthanasia. The total food intake
was calculated by measuring the daily consumption of food
in grams as the difference between the food provided on the
previous day and that left unconsumed per cage (2 rats per
cage; Jeremic et al., 2018).
After 4 weeks of dietary/pharmacological treatment and short-
term anesthesia by diethyl ether, blood samples were collected
from the overnight (12 h)-fasted rats during while sacrificing
the rats. Plasma samples were obtained from the centrifugation
of heparinized blood at 1,800 g for 15min and were stored in
a −80◦C freezer until further FA analysis. Additionally, serum
samples were obtained by collecting blood from rats without
anticoagulant followed by centrifugation.
Diets and Drugs
In our research we used three different diets in which are different
amount of methionine and B vitamins (folic acid, B6, and B12).
We used standard rodent chow (3.8 g/kg of methionine, 2 mg/kg
folic acid, 0.03 mg/kg B6, and 70 mg/kg B12); a diet enriched
in methionine (7.7 g/kg of methionine) with no deficiency of
B vitamins (2 mg/kg folic acid, 0.03 mg/ kg B6, and 70 mg/kg
B12); a diet enriched in methionine and deficient in B vitamins
(7.7 g/kg of methionine, 0.08 mg/kg folic acid, 0.01 mg/kg B6,
and 0.01 mg/kg B12; Nikolic Turnic et al., 2018). All diets were
purchased from Mucedolla, Milan, Italy. All drugs as analytical
substances (atorvastatin and simvastatin) were obtained from
Sigma Aldrich, Germany.
Determination of Homocysteine (Hcy)
As it previously described, total serum Hcy concentrations were
determined with a high-performance liquid chromatography
(HPLC) procedure (Ulbink et al., 1991).
Determination of Fatty Acid Profile in
Plasma
The fatty acid profile of total lipids in plasma was determined
using the described method (Glaser et al., 2010) with few
modifications. Briefly, 1.5ml HCl in methanol (3M HCl in
methanol) was added to 100 µl of plasma and heated at 85◦C
for 45min. After cooling to room temperature, 1ml hexane was
added, and the sample was vortexed for 30 s and centrifuged
for 10min at 1,800x g. Then, the hexane layer, which was
approximately 600 µl, was evaporated to dryness in a nitrogen
stream. was dissolved in 10 µl of hexane and 1 µl was
injected into a gas chromatograph (SHIMADZU 2014 168 Third
Avenue Waltham, MA USA 02451). The gas chromatograph
was equipped with a RESTEK Rtx 2330 capillary column (60m
× 0.25mm × 0.2µm). The temperature programme increased
from 140 to 210◦C at 3◦/min. Individual fatty acids were
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identified compared with the retention times of PUFA-2 fatty
acidmethyl ester commercial standards (Supelco, Inc., Bellefonte,
Pennsylvania, USA). The results are presented as the percentage
of the total FA composition (Veselinovic et al., 2017).
Estimated Elongase and Desaturase
Activities (Desaturase Index)
The activities of enzymes involved in FA biosynthesis, including
desaturases and elongases, were estimated as product-to-
precursor ratios (desaturase and elongase index) as previously
described (Tepsic et al., 2013). The estimated activity of delta-
5-desaturase was calculated as the 20:4ω-6/20:3ω-6 ratio (D5-
desaturase index), while the 18:3ω-6/18:2ω-6 ratio was used
to estimate delta-6-desaturase activity (D6-desaturase index).
Also, delta-9-desaturase, also called stearoyl-CoA desaturase
(SCD) and elongase indices were obtained from 16:1/16:0 (SCD-
16 index), 18:1/18:0 (SCD-18 index), and 18:0/16:0 (elongase
index) ratios.
Statistical Analyses
Statistical analysis was done by using SPSS for Windows
version 22. The results are presented as the mean ± standard
deviation/standard error of mean (mean± SD/SEM). Differences
between the groups were confirmed by one-way ANOVA
followed by the Tukey post hoc test or by the Kruskal-Wallis
test and Mann-Whitney U-test depending on the normality.
Significance level was 0.05.
RESULTS
Food Intake and Body Weight
We found significant differences in body weight and food intake
in all groups as we previously published (Jeremic et al., 2018).
We found significant differences in body weight and food intake
in all groups. The MFD group consumed less food and had lower
weight gain, and heart and liver weight than the S and M groups,
while M had only lower weight gain and food consumption than
in the S group. Additionally, a high-methionine diet caused a
statistically significant increase in the heart weight/body weight
and the liver weight/body weight compared to that of the
control (Jeremic et al., 2018).
Homocysteine Concentration
The highest levels of homocysteine were observed in MFD
groups, and lowest levels in S groups (Table 1). Well,
hyperhomocysteinemia was achieved in the groups fed
the methionine-enriched special diets, and based on this
observation, we confirmed normal homocysteine levels in the
S, S+ATO and S+SIM groups; mild hyperhomocysteinemia
(Hcy = 15–30 µmol/L) in the M, M+ATO and M+SIM groups;
and severe hyperhomocysteinemia (Hcy> 31 µmol/L) in the
MFD, MFD+ATO, and MFD+SIM groups (Nikolic et al., 2018;
Nikolic Turnic et al., 2018) (Supplementary Table 1).
TABLE 1 | Levels of homocysteine in all groups.
Groups Total homocysteine in serum (µmol/l)
S M MFD
8.11 ± 0.1 22.43 ± 0.3 63.89 ± 0.1
S + ATO M + ATO MFD + ATO
11.57 ± 3.27 16.10 ± 4.32 59.41 ± 7.12
S + SIM M + SIM MFD + SIM
11.41 ± 1.92 30.22 ± 5.71 58.51 ± 4.49
Data are presented as mean value ± standard deviation (M ± SD) (n = 8 rats per group).
Effects of Different Dietary Manipulation
and Statin Treatment on Fatty Acid
Composition in Total Plasma Lipids
From the plasma samples, we determined the percentage of
individual FAs in the plasma lipids in all the study groups, and
the results are shown in Table 2. First, we compared the FA
status of rats fed different dietary regimes. When we examined
the groups fed a standard diet (S, S+ATO, S+SIM), our results
showed a significant increase in linoleic acid (LA, 18:2, ω-6)
and eicosapentaenoic acid (EPA, 20:5, ω-3) levels in the S+ATO
group compared with the controls. Additionally, we also found
increased oleic acid (18:1 ω-9), LA, γ-linolenic acid (GLA, 18:3,
ω-6) and EPA levels as well as decreased arachidonic (AA, 20:4,
ω-6) and docosahexaenoic acid (DHA, 22:6, ω-3) levels in the
simvastatin-treated rats (S+SIM) compared with the controls.
The only difference between the S+ATO and S+SIM groups
was lower levels of docosapentaenoic acid (DPA 22:5, ω-3) in
the simvastatin-treated group. Among the groups with mild
hyperhomocysteinemia (M,M+ATO andM+SIM), we observed
a similar fatty acid composition in the M and M+ATO groups.
However, when we compared the M+SIM and M groups, we
found higher levels of stearic acid (18:0), LA and EPA and lower
levels of DPA, DHA, and AA. The last two FAs were also lower
in the M+SIM group compared with the M+ATO group. In the
groups with severe hyperhomocysteinemia, including the MFD,
MFD+ATO, and MFD+SIM groups, we found more differences
between the group exposed to atorvastatin and its appropriate
control group (MFD) than in the aforementioned groups. Thus,
oleic acid and docosatetraenoic (DTA, 22:4, ω-6) levels were
higher, while stearic acid, EPA, and DHA levels were lower
than in the MFD group. Similar to the other rats that were
given simvastatin, dihomo-gamma-linolenic acid (DGLA, 20:3,
ω-6), EPA, DPA, and DHA levels were lower than in the MFD
group. Compared with the M+ATO group, M+SIM had a lower
proportion of DGLA and DPA.
As is shown in Table 3, there were no significant differences in
the groups regarding their estimated D6-desaturase and elongase
activities. Elevated SCD-18 index, as an estimated activity of
this enzyme, was detected in the S+SIM group compared with
its control group S and in the MFD+ATO group compared
with both the MFD and MFD+SIM groups. Furthermore,
simvastatin elevated indices of SCD-16 in all groups, while
atorvastatin reduced these indices, although these changes were
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not statistically significant in the MFD groups. Both statins
decreased D5-desaturase index in the animals fed a standard diet,
as well as in the M+SIM group, but increased the estimated
activity of this enzyme in the MFD+SIM group.
Effects of Different Dietary Manipulation
and Statin Treatments on Total SFA, MUFA,
and PUFA
Animals with Hhcy (the M and MFD groups, Figure 1A) treated
with simvastatin had significantly higher SFA levels than the
groups taking atorvastatin. Simvastatin also increased MUFA
levels in the S group. Both statins elevated MUFA levels in the
MFD group (Figure 1C), while PUFA levels were lower in the
MFD+SIM group than in its control (MFD), as well as in the
M+SIM group compared with the M+ATO group (Figure 1B).
Effects of Different Dietary Manipulation
and Statin Treatments on Total ω-3 and ω-6
Amounts and the ω-6/ ω-3 Ratio
The levels of total ω-3 PUFAs in plasma samples were
significantly decreased in all the groups treated with simvastatin
(S+SIM, M+SIM and MFD+SIM) compared to the appropriate
control groups and groups treated with atorvastatin (Figure 1D).
Accordingly, the ω-6/ω-3 ratios were significantly higher in all
the groups on simvastatin compared with their controls and
the atorvastatin groups (Figure 1F). Additionally, in the groups
with severe hyperhomocysteinemia (MFD group), atorvastatin
significantly reduced ω-3 levels and increased the ω-6/ω-3
ratio (Figures 1D–F).
Correlation Analysis of Hcy Levels and the
Fatty Acid Profile
Figure 2 displays only variables that were significantly correlated
with Hcy levels. Only palmitic acid and SCD-18 index were
moderately positively correlated with homocysteine levels in all
the groups (Figures 2A,E). In contrast, EPA, total PUFA, and ω-
6 FA levels and elongase index were weakly negatively correlated
with homocysteine levels (Figures 2B–D,F).
DISCUSSION
The present study aimed to examine the associations of statins,
the FA profile, and homocysteine levels, which are implicated in
the pathology of cardiovascular diseases.
Our experimental model of diet-inducedHhcy is an absolutely
adequate model for Hhcy, as most chronic changes associated
with homocysteine levels are related to diet in humans.
The two different dietary regimes induced different degrees of
Hhcy: moderate and severe. In all groups, statins did not change
the levels of homocysteine, which is similar to our previously
published results; thus, we could clearly comment on the effects
of these lipid-lowering drugs on the FA profile (Nikolic et al.,
2018; Nikolic Turnic et al., 2018). The only difference in the FA
profile depending on the dietary treatment was observed in the
level of ALA, which was slightly higher in the group of animals
fed a diet enriched inmethionine with no deficiency in B vitamins
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TABLE 3 | The estimated plasma desaturases and elongase activities in rats on different treatments and dietary regimes (n = 8 rats per group).
Groups S S + ATO S + SIM M M + ATO M + SIM MFD MFD + ATO MFD + SIM
Enzyme index X ± SD X ± SD X ± SEM X ± SD X ± SD X ± SD X ± SD X ± SD X ± SD
SCD-16 0.08 ± 0.01 0.06 ± 0.01* 0.09 ± 0.02# 0.07 ± 0.01 0.05 ± 0.00* 0.10 ± 0.02*# 0.07 ± 0.02 0.06 ± 0.01 0.08 ± 0.01
SCD-18 0.46 ± 0.02 0.52 ± 0.12 0.74 ± 0.09* 0.40 ± 0.03 0.48 ± 0.01 0.47 ± 0.01 0.43 ± 0.02 0.95 ± 0.03*** 0.64 ± 0.06##
D6-desaturase 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 0.03 ± 0.01 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.00
D5-desaturase 22.22 ± 1.85 13.31 ± 0.08** 13.91 ± 1.84** 24.23 ± 3.80 23.92 ± 1.52 16.80 ± 2.33# 19.91 ± 3.62 13.18 ± 0.94 23.44 ± 3.39*#
Elongase 0.70 ± 0.03 0.79 ± 0.15 0.70 ± 0.05 0.69 ± 0.01 0.70 ± 0.04 0.82 ± 0.02 0.69 ± 0.03 0.56 ± 0.03 0.64 ± 0.04
Date are expressed as the mean ± SD. SCD, Stearoyl-CoA desaturase; D5-desaturase, delta-5 desaturase; D6-desaturase, delta-6 desaturase. *p < 0.05, **p < 0.01, ***p < 0.001
compared to appropriate control group in the same dietary intervention; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to atorvastatin group in the same dietary intervention;
aap < 0.01 compared with S group.
FIGURE 1 | Levels of SFA (A), PUFA (B) and MUFA (C), ω−3 PUFA (D), ω−6 PUFA (E), and ω−6 /ω-3 ratio (F) in all investigated groups (n = 8 rats per group).
Results are expressed as mean ± SEM. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
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FIGURE 2 | Regression analyses. Confirmed correlation was observed between Hcy and: Palmitic acid (A), EPA (B), PUFA (C), ω−6 PUFA (D), SCD-18 index
(E), and Elongase (F) among all groups (8 rats per group). EPA, eicosapentaenoic acid; PUFA, polyunsaturated fatty acids; SCD-18, Stearoyl-CoA desaturase
(18:1/18:0).
(M). This confirms that all the alterations in FA composition of
plasma lipids are related to statin treatments.
There is a large pool of data supporting the pleiotropic
effects of statins on the cardiovascular system (Colhoun et al.,
2004; Fauchier et al., 2008; Nassief and Marsh, 2008). Many
researchers have reported improved heart function, decreased
cholesterol levels and reduced CVD symptoms (Baszczuk et al.,
2014; Zhang et al., 2014). Other studies suggest benefits of
statins in the reduction of stroke risk, atrial fibrillation, and
incidence of myocardial infarction, as well as for the treatment
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of chronic kidney disease, rheumatologic diseases and multiple
sclerosis (Colhoun et al., 2004; Schaffer et al., 2014). Nevertheless,
there are no data focused on the specific roles of the FA
contents in all these conditions during statin treatment. Studies
evaluating the effects of statins on plasma FA metabolism
in humans are sparse and published data are contradictory
(Risé et al., 2001; Bird et al., 2018).
In the first part of this study, we examined the effects
of different dietary regimes and atorvastatin and simvastatin
on individual fatty acids. Total ω-3 PUFA levels significantly
decreased and the ω-6/ω-3 ratio in plasma samples increased in
the simvastatin-treated groups compared with both the control
and atorvastatin-treated groups. Furthermore, in the MFD group
with severe Hhcy, atorvastatin treatment lowered ω-3 levels,
which induced a higher ω-6/ω-3 ratio. Simultaneously, statins
did not changeω-6 PUFA levels. However, level of LA was mostly
higher and AA was lower in statin treated groups, suggesting
decreased conversion from LA to AA. Considering that AA
is the most pro-inflammatory FA and a precursor of several
inflammatory eicosanoids, these findings suggest that statins,
especially simvastatin, may have anti-inflammatory effects. The
other possibility is that AA is rapidly converted into eicosanoids,
thereby promoting inflammation. The clarification of the effects
of statins on inflammation require further investigation, but
statin use obviously increase the ω-6/ω-3 ratio (Takahashi et al.,
2017), which usually result in a net increase in inflammation
and thrombogenesis (de Lorgeril et al., 2013), as well as further
CVD development and progression. Taking into account the
importance of high ω-3 PUFA levels not only for cardiovascular
health, but also for other chronic diseases, significant decrease
in ω-3 PUFA levels in statin use found in this study, is of a
particular importance.
It is interesting that elevated SCD-18 index, as an estimation
of desaturase activity, was found in the simvastatin groups fed a
standard diet and a diet enriched with methionine and deficient
in B vitamins (MFD), but in severe Hhcy atorvastatin treatment
increased SCD-18 index evenmore than simvastatin. Simvastatin
also increased SCD-16 index in the M group, while atorvastatin
reduced the estimated activity of this enzyme S+ATO and
M+ATO groups. Both statins decreased D5-desaturase index
in the animals fed a standard diet. Simvastatin treatments
decreased D5-desaturase index in the control group and in
mild Hhcy but increased the activity of this enzyme in severe
hyperhomocysteinemia. In human studies, simvastatin increased
D5-desaturase activity in dyslipidaemia (Jula et al., 2005; Nozue
and Michishita, 2015), but atorvastatin decreased D5-desaturase
activity in metabolic syndrome model rats (Al Mamun et al.,
2017). It is important to point out that there were no differences
among the groups in the estimated activities of D6-desaturase
and elongase. This can lead to changes in the relative proportions
of longer chain PUFAs.
Meta-analysis of randomized control trials indicated that high
consumption of ω-3 PUFA decreases plasma Hcy concentrations
(Huang et al., 2011). Moreover, the same authors showed that
ω-3 PUFA upregulates mRNA expression, while n-6 PUFA
downregulates the mRNA expression of key genes involved
in homocysteine metabolism (Huang et al., 2013). These
mechanisms could be one of the possible reasons for the altered
FA levels during severe Hhcy. Other authors (Severus et al., 2001)
examined the significant roles of Hcy in homocysteine-related
cardiovascular disease treated withω-3 PUFA and concluded that
homocysteine and FAs are two very important factors that may
have a causal relationship.
Previous data confirmed that Hcy as a thiol could modulate
cardiovascular function and act through various mechanisms,
such as induce endothelial dysfunction leading to the alterations
in arterial structure. Some of the proposed mechanisms include
a proliferation of vascular smooth muscle cells, endothelial
dysfunction, oxidative damage, collagen synthesis, and the
deterioration of the arterial wall elastic material (Durand et al.,
2001; Piolot et al., 2003; Schaffer et al., 2014).
In addition to ω-3 and ω-6 PUFAs, other fatty acids in
our study were also changed. Simvastatin treatments induced
an increase in SFAs in animals with Hhcy compared to
atorvastatin. Both statins elevated MUFAs in the group with
severe Hhcy. In the second part of this study, we correlated
the levels of Hcy and FAs in blood samples. Levels of EPA,
total PUFAs andω-6 PUFA negatively correlated, while saturated
palmitic acid and SCD-18 moderately positively correlated with
homocysteine levels. According to our results, homocysteine is
a biomarker of cardiovascular disorder, and high levels of ω-
3 is an indicator of cardiovascular health. We can indirectly
observe that folate, B12 and B6 intake were associated with both
serum ω-3 and ω-6 PUFAs and homocysteine levels. In line
with this result, an observational study suggested that higher
dietary intake of ω-3 PUFAs was associated with decreased
plasma homocysteine levels (Berstad et al., 2007). Regarding the
levels of ω-6 FAs, some studies have examined the associations
between plasma ω-6 PUFA levels and Hcy concentrations
(Huang et al., 2012a,b). Some authors have concluded that
plasma ω-6 PUFA was significantly positively associated with
plasma homocysteine in some conditions, such as in vegetarians,
diabetes patients, and the general population (Huang et al.,
2012a,b). In the other studies, however, ω-6 PUFA was not
associated with plasma homocysteine in omnivores, while we
found a slight negative correlation. The results from this study
are in accordance with the assumptions that omega-6 FAs
have negative effects on the cardiovascular system as well as
homocysteine; thus, the positive connection between Hcy and
omega-6 FAs in our study is completely expected. Additionally,
simvastatin exerts stronger effects on FA status during Hhcy
than atorvastatin.
CONCLUSION
Statins considerably affect FA status in animals with
hyperhomocysteinemia, in particular simvastatin. They decrease
the levels of cardioprotective ω-3 PUFA. Lower serum Hcy
concentrations were observed in association with higher EPA,
ω-6 and total PUFA levels. Moreover, higher levels of Hcy
correlate with elevated atherogenic palmitic acid.
These findings pointed for the significant role of ω-3 FAs
in lowering homocysteine concentrations, as well as the role of
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statins in FA status and changing the risk for CVD in general
as a consequence. Our results also suggest that statin use should
be followed by ω-3 PUFA supplementation, which is obviously
needed during the statin treatments.
Prospective studies are required to clarify whether a higher
ω-3 or ω-6 FAs status at baseline is associated with the
future decrease in blood homocysteine levels and the risk of
homocysteine-related diseases.
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